Robust and highly selective proton MRSI on a clinical 3 T system using a second order gradient insert, for application in schizophrenia
使用二阶梯度插入的临床 3 T 系统上的鲁棒性和高选择性质子 MRSI,用于精神分裂症的应用
基本信息
- 批准号:10741355
- 负责人:
- 金额:$ 46.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-21 至 2025-09-20
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAssessment toolBiological MarkersBrainBrain DiseasesBrain imagingBrain regionCephalicCholineChronicClinicClinicalClinical ResearchDataDevelopmentDiseaseEngineeringEnvironmentEtiologyEvaluationExclusionFunctional disorderGlutamatesGlutamineGoalsHeadHeterogeneityImageImaging DeviceLipidsLiteratureMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMapsMeasurementMetabolicMethodsModalityMorphologic artifactsNeurologicNeuronal DysfunctionPathogenesisPatientsPerformancePhysiologic pulsePlayRecoveryReportingReproducibilityResearchResolutionRoleScanningScheduleSchizophreniaSeverity of illnessShapesSignal TransductionSliceSystemTechnologyTestingTimeTissuesTranslatingTranslationsUncertaintyWorkclinical applicationclinically significantcohortcraniumdesignfirst episode psychosisfrontal lobegray matterhealthy volunteerimaging capabilitiesimaging modalityimaging studyimprovedin vivointerestmacromoleculemagnetic resonance spectroscopic imagingmetabolic imagingmetabolic profilenew therapeutic targetnovelpersonalized medicinepreventschizophrenia spectrum disordersimulationspectroscopic imagingtreatment effectvolunteer
项目摘要
PROJECT SUMMARY –
The glutamate hypothesis of schizophrenia has generated significant interest in the utility of Magnetic Resonance
Spectroscopy and Spectroscopic Imaging (MRS/MRSI) to study the pathophysiology of schizophrenia in recent
times. The glutamate hypothesis provides a complementary perspective to the well-established dopaminergic
hypothesis, suggesting that dysfunction of the glutamatergic system plays a role in the etiology of schizophrenia.
Previous MRS/MRSI studies conducted have reported alterations of glutamate (Glu) and glutamine (Gln) and
Glx (Glu + Gln) in various brain regions, consistent with neuronal dysfunction in chronic stages of the disease.
The robust and reliable acquisition of MRSI data is however hindered by extracranial lipid contaminants. Most
extracranial lipid suppression methods reported to-date provide inadequate lipid signal suppression, to allow
artifact-free spectroscopic evaluation of cortical grey matter proximal to the skull. As a result, MRSI studies in
schizophrenia conducted to-date at 3 T have two major limitations: 1) exclusion of cortical tissue proximal to
extracranial lipids, and 2) uncertainties associated with Glu/Gln separation, thus predominantly reporting Glx
changes. Because glutamatergic activity is inferred from the Glu/Gln ratio, it is critical to develop accurate and
separate quantitation of Glu and Gln to further the value of testing the glutamate hypothesis.
This work involves the development of a high resolution (~ 5 x 5 x 10 mm3) 3D proton MRSI method using
ECLIPSE, a second order gradient insert, for highly selective elliptical localization over an axial plane. High
selectivity and unparalleled extracranial lipid suppression was previously demonstrated with ECLIPSE, which
allows artifact-free interrogation of cortical tissue adjacent to the skull. The MRSI acquisition will be extended
with an optimized multiple-echo time (TE) acquisition combined with a macromolecule targeted inversion
recovery component to nullify the macromolecular baseline. In combination the proposed MRSI method is
expected to allow reliable quantification of Glu/Gln. Following development of the MRSI sequence, robustness,
reproducibility metrics, and Glu/Gln quantification performance will be evaluated in phantom and on a healthy
cohort of volunteers, followed by tolerance and translatability of the methods evaluated on a heterogenous cohort
of first episode psychosis or patients with recent onset schizophrenia spectrum disorders.
The successful completion of the proposed methods will allow reliable quantitative MRS images of Glu and Gln,
among other commonly detected metabolites, over an axial slab including frontal cortical gray matter proximal
to the skull. Given that the frontal region is the most significantly impacted by schizophrenia, the ability provided
for reliable metabolic images that are sensitive to altered glutamatergic activity is expected to have a high impact
by providing a reliable metabolic imaging tool for characterizing disease severity, heterogeneity, and treatment
effects in patients. The development of reliable Glu/Gln quantification with MRSI at 3 T has further clinical
significance, since the 3 T field strength is the most accessible high field MRI system in the clinical setting.
项目概要-
精神分裂症的谷氨酸假说引起了人们对磁共振成像的极大兴趣。
波谱和波谱成像(MRS/MRSI)在精神分裂症病理生理研究中的应用
次谷氨酸假说提供了一个补充的观点,以完善的多巴胺能
这一假说,表明神经系统功能障碍在精神分裂症的病因中起作用。
先前进行的MRS/MRSI研究已经报道了谷氨酸(Glu)和谷氨酰胺(Gln)的改变,
Glx(Glu + Gln)在不同的大脑区域,符合神经元功能障碍的慢性阶段的疾病。
然而,颅外脂质污染物阻碍了MRSI数据的稳健和可靠采集。最
迄今为止报道的颅外脂质抑制方法提供的脂质信号抑制不足,
颅骨近端皮质灰质的无伪影光谱评估。因此,MRSI研究在
迄今为止在3 T下进行精神分裂症治疗有两个主要局限性:1)排除了邻近
颅外脂质,和2)与Glu/Gln分离相关的不确定性,因此主要报告Glx
变化由于谷氨酸能活性是从Glu/Gln比率推断的,因此开发准确且
单独定量Glu和Gln以进一步检验谷氨酸假设的价值。
这项工作涉及开发高分辨率(~ 5 x 5 x 10 mm 3)3D质子MRSI方法,
ECLIPSE,二阶梯度插入,用于轴向平面上的高度选择性椭圆定位。高
ECLIPSE先前已证明具有选择性和无与伦比的颅外脂质抑制作用,
允许无伪影地询问邻近颅骨的皮质组织。MRSI收购将延长
采用优化的多回波时间(TE)采集与大分子靶向反转相结合
回收组分以使大分子基线无效。结合所提出的MRSI方法,
预期允许Glu/Gln的可靠定量。在开发MRSI序列后,稳健性,
再现性指标和Glu/Gln定量性能将在体模和健康
志愿者队列,然后在异质性队列中评价方法的耐受性和可翻译性
首次发作的精神病患者或近期发作的精神分裂症谱系障碍患者。
所提出的方法的成功完成将允许Glu和Gln的可靠定量MRS图像,
在其他常见的代谢物中,在包括额叶皮质灰质近端的轴向板上,
头骨。鉴于额叶区域是精神分裂症最显著的影响,
对于可靠的代谢图像,对改变的代谢能活动敏感,
通过提供可靠的代谢成像工具来表征疾病的严重性、异质性和治疗,
对患者的影响。在3 T MRSI上可靠的Glu/Gln定量的发展具有进一步的临床意义。
这是非常重要的,因为3 T场强是临床环境中最容易使用的高场MRI系统。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHATHURA KUMARAGAMAGE其他文献
CHATHURA KUMARAGAMAGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
The potential of using student-conducted ethnographic research as a formative assessment tool in CLIL and EMI courses
在 CLIL 和 EMI 课程中使用学生进行的民族志研究作为形成性评估工具的潜力
- 批准号:
24K04145 - 财政年份:2024
- 资助金额:
$ 46.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
I-Corps: Remote monitoring and assessment tool for spinal care patients
I-Corps:脊柱护理患者的远程监测和评估工具
- 批准号:
2321802 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Standard Grant
SBIR Phase I: PenEEG: An Objective Assessment Tool for Concussion and Recovery Management
SBIR 第一阶段:PenEEG:脑震荡和恢复管理的客观评估工具
- 批准号:
2304353 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Standard Grant
Developing a new risk and needs assessment tool for young people who have displayed harmful sexual behaviour
为表现出有害性行为的年轻人开发新的风险和需求评估工具
- 批准号:
2886506 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Studentship
Development of the Dementia-Friendly Environmental Assessment Tool for Japanese care and nursing homes
为日本护理院和疗养院开发痴呆症友好型环境评估工具
- 批准号:
22KJ0474 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Implementation of an impact assessment tool to optimize responsible stewardship of genomic data in the cloud
实施影响评估工具以优化云中基因组数据的负责任管理
- 批准号:
10721762 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
I-Corps: Sensor-based frailty assessment tool using a smart watch
I-Corps:使用智能手表的基于传感器的虚弱评估工具
- 批准号:
2311611 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Standard Grant
Injury prevention for rugby-related concussion: development of a comprehensive tackle assessment tool
橄榄球相关脑震荡的伤害预防:开发综合铲球评估工具
- 批准号:
23K16737 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of a diagnostic assessment tool and training app for dyscaliculia to apply in medical treatment and education.
开发计算障碍诊断评估工具和培训应用程序,以应用于医疗和教育。
- 批准号:
23K02570 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical Grip Training and Assessment Tool for Rheumatoid Arthritis
类风湿关节炎的临床握力训练和评估工具
- 批准号:
10050499 - 财政年份:2023
- 资助金额:
$ 46.06万 - 项目类别:
Collaborative R&D